SCHEMBL6317587

SCHEMBL6317587

CCCCCCCCC([CH]CC(C)CCCC(C)CCCC(C)CCCC(C)C)CCCCCCCC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
ACE2 Q9BYF1 1/20 0.41
BLM P54132 1/20 0.35
PTPN1 P18031 3/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
ADH1B P00325 1/20 0.34
ADH1C P00326 1/20 0.34
ADH1A P07327 1/20 0.34
ADH4 P08319 1/20 0.34
ADH7 P40394 1/20 0.34
PRKD3 O94806 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
PRKCA P17252 1/20 0.33
PRKCH P24723 1/20 0.33
PRKCI P41743 1/20 0.33
PRKCE Q02156 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2486667 0.91 ACE2 (0.42) LMNAACE2ADH1BADH1CADH1A
SCHEMBL2483906 0.91 ACE2 (0.42) LMNAACE2ADH1BADH1CADH1A
SCHEMBL2485561 0.91 ACE2 (0.42) LMNAACE2ADH1BADH1CADH1A
SCHEMBL23363677 0.82 LMNA (0.74) LMNAACE2BLMPTPN1MEN1
SCHEMBL672089 0.82 LMNA (0.74) LMNAACE2BLMPTPN1MEN1
SCHEMBL38655840 0.82 LMNA (0.74) LMNAACE2BLMPTPN1MEN1
SCHEMBL23672996 0.82 LMNA (0.74) LMNAACE2BLMPTPN1MEN1
SCHEMBL31509473 0.82 LMNA (0.74) LMNAACE2BLMPTPN1MEN1
SCHEMBL10959498 0.82 LMNA (0.74) LMNAACE2BLMPTPN1MEN1
SCHEMBL31509120 0.82 LMNA (0.74) LMNAACE2BLMPTPN1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050152959-A1 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell TRANSGENE S. A. (FR) 2005-07-14 US disclosed
EP-1465597-A2 USE OF A LYSOLIPID FOR THE PREPARATION OF A COMPOSITION FOR TRANSFECTION OF A POLYNUCLEOTIDE INTO A CELL TRANSGENE S.A. (FR) 2004-10-13 EP disclosed
WO-2003052095-A2 USE OF A LYSOLIPID FOR THE PREPARATION OF A COMPOSITION FOR TRANSFECTION OF A POLYNUCLEOTIDE INTO A CELL TRANSGENE S.A. (FR) 2003-06-26 WO disclosed
US-4935520-A ANTITUMOR AND ANTICARCINOGENIC AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1990-06-19 US disclosed
EP-0108565-A2 Phospholipids, their production and use thereof Takeda Chemical Industries, Ltd. (JP) 1984-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050152959-A1 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell LPCAT1, LPCAT3, LCLAT1 LMNA 91/4885ACE2 2618/4885BLM 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.